Home > Oncology > ASCO 2022 > Panitumumab beats bevacizumab in RAS wild-type left-sided metastatic colorectal cancer

Panitumumab beats bevacizumab in RAS wild-type left-sided metastatic colorectal cancer

Presented By
Dr Takayuki Yoshino, National Cancer Center Hospital East, Japan
Conference
ASCO 2022
Trial
Phase 3, PARADIGM
Panitumumab was superior to bevacizumab when added to mFOLFOX6 as first-line therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC), especially in patients with left-sided tumours. The results of the phase 3 PARADIGM trial support mFOLFOX6 plus panitumumab as first-line therapy in patients with RAS wild-type left-sided mCRC. Adding an EGFR inhibitor or VEGF inhibitor to chemotherapy improves the overall survival (OS) of patients with mCRC significantly [1]. In patients with RAS wild-type, left-sided, colorectal tumours, the benefit of an EGFR inhibitor may be enriched [2]. The phase 3 PARADIGM trial assessed this matter by randomising 823 patients with RAS wild-type metastatic colorectal cancer 1:1 to mFOLFOX6 and the EGFR inhibitor panitumumab or to mFOLFOX6 plus the VEGF inhibitor bevacizumab. In total, 604 patients had left-sided tumours. The primary endpoints of this trial were OS in the left-sided population and OS in the o...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on